Abstract:
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
Abstract:
Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3, 20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.
Abstract:
Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contains one or more carrageenans, including lambda carrageenan. Also disclosed are methods for making and using the compositions.
Abstract:
The present invention relates to implantable male contraceptive devices. An ethylene vinyl acetate copolymer based implant (10) is described for delivery of an androgen (15) and a system including an ethylene vinyl acetate copolymer based implant (10) as well as a second implant are described for the administration of both androgen and a sterilitant. These implants may be used to provide contraception for men, as well as, for hormone therapy, treatment of enlarged prostate and other ailments.
Abstract:
Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified antiretroviral agents comprising NNRTIs and NRTIs. Also disclosed are methods for making and using the compositions. Also disclosed are intravaginal rings for delivering water-soluble compounds, and preferably high molecular weight water-soluble polymers at essentially a zero order rate. The rings include an outer layer of non-water-swellable elastomer, and preferably high molecular weight water-soluble polymer and an inner layer of the water-soluble polymer, which is imbedded in the outer layer, and an aperture through the outer layer for release thereof only through that aperture.
Abstract:
The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.
Abstract:
Disclosed are male contraceptives containing a peptide and analogs thereof having an amino acid sequence corresponding to the second extracellular domain of a mammalian occludin. The peptides may be linked to a carrier targeting testicular cells, preferably to a modified follicle stimulating hormone. Methods of producing such a contraceptive, and a method of use are also disclosed.
Abstract:
Disclosed are antiviral compositions comprising an effective amount of an antiviral agent comprising one or more polysaccharides and one or more lectins for inhibiting a SARS- CoV infection, particularly caused by SARS-CoV-1, or SARS-CoV-2.
Abstract:
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is suitable for four quarterly product-use cycles or for a 365-day product-use cycle.